| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
TP53 mutation and survival in chronic lymphocytic leukemia.
|
J Clin Oncol
|
2010
|
3.26
|
|
2
|
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
|
J Clin Oncol
|
2011
|
3.21
|
|
3
|
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
|
J Clin Oncol
|
2012
|
3.00
|
|
4
|
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial.
|
Blood
|
2010
|
2.87
|
|
5
|
miR-34a as part of the resistance network in chronic lymphocytic leukemia.
|
Blood
|
2008
|
2.58
|
|
6
|
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.
|
Blood
|
2008
|
2.46
|
|
7
|
Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.
|
J Clin Oncol
|
2006
|
2.15
|
|
8
|
Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
|
Blood
|
2009
|
2.01
|
|
9
|
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
|
J Clin Oncol
|
2009
|
2.00
|
|
10
|
Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival.
|
Haematologica
|
2007
|
1.99
|
|
11
|
High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations.
|
Blood
|
2012
|
1.58
|
|
12
|
Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes.
|
Blood
|
2005
|
1.16
|
|
13
|
Intraoperative MRI to guide the resection of primary supratentorial glioblastoma multiforme--a quantitative radiological analysis.
|
Neuroradiology
|
2005
|
1.15
|
|
14
|
NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG.
|
Blood
|
2013
|
1.09
|
|
15
|
Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism.
|
Bioorg Med Chem
|
2013
|
1.07
|
|
16
|
A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia.
|
Cancer Res
|
2009
|
0.94
|
|
17
|
Rapid analysis of Forster resonance energy transfer by two-color global fluorescence correlation spectroscopy: trypsin proteinase reaction.
|
Biophys J
|
2005
|
0.93
|
|
18
|
Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia.
|
Haematologica
|
2009
|
0.91
|
|
19
|
Effects of subthalamic nucleus stimulation on striatal dopaminergic transmission in patients with Parkinson's disease within one-year follow-up.
|
J Neurol
|
2008
|
0.89
|
|
20
|
DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing.
|
Blood
|
2010
|
0.89
|
|
21
|
Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease.
|
J Med Chem
|
2012
|
0.87
|
|
22
|
BRAF mutations in chronic lymphocytic leukemia.
|
Leuk Lymphoma
|
2012
|
0.87
|
|
23
|
Identification of novel Kv1.3 blockers using a fluorescent cell-based ion channel assay.
|
J Biomol Screen
|
2005
|
0.85
|
|
24
|
Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer.
|
Int J Cancer
|
2006
|
0.85
|
|
25
|
Development of a 1-microl scale assay for mitogen-activated kinase kinase 7 using 2-D fluorescence intensity distribution analysis anisotropy.
|
J Biomol Screen
|
2002
|
0.83
|
|
26
|
Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial.
|
Blood
|
2012
|
0.83
|
|
27
|
Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease.
|
J Med Chem
|
2015
|
0.83
|
|
28
|
Property- and structure-guided discovery of a tetrahydroindazole series of interleukin-2 inducible T-cell kinase inhibitors.
|
J Med Chem
|
2014
|
0.82
|
|
29
|
Fragment-based identification of Hsp90 inhibitors.
|
ChemMedChem
|
2009
|
0.82
|
|
30
|
Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia.
|
Cancer
|
2013
|
0.80
|
|
31
|
Mutation analysis of the TNFAIP3 (A20) tumor suppressor gene in CLL.
|
Int J Cancer
|
2010
|
0.80
|
|
32
|
The impact of psychiatric comorbidity on the return to work in patients undergoing herniated disc surgery.
|
J Occup Rehabil
|
2011
|
0.80
|
|
33
|
Peptide based adsorbers for therapeutic immunoadsorption.
|
Ther Apher Dial
|
2003
|
0.79
|
|
34
|
Investigation of 3 industry-wide applied storage conditions for compound libraries.
|
J Biomol Screen
|
2006
|
0.78
|
|
35
|
Investigation of time-dependency of intracranial brain shift and its relation to the extent of tumor removal using intra-operative MRI.
|
Neurol Res
|
2003
|
0.77
|
|
36
|
Unusual penetrating cranio-orbital injury by a cut-off wheel.
|
J Craniofac Surg
|
2004
|
0.77
|
|
37
|
Metabolism and pharmacokinetics of JM6 in mice: JM6 is not a prodrug for Ro-61-8048.
|
Drug Metab Dispos
|
2012
|
0.76
|
|
38
|
Novel MK2 inhibitors by fragment screening.
|
Comb Chem High Throughput Screen
|
2009
|
0.76
|
|
39
|
Increase of frequency in deep brain stimulation relieves apraxia of eyelid opening in patients with Parkinson's disease: case report.
|
Neurosurgery
|
2008
|
0.75
|
|
40
|
A multiplexed approach to hit finding.
|
Curr Opin Drug Discov Devel
|
2009
|
0.75
|
|
41
|
Correction: Pelvic Belt Effects on Health Outcomes and Functional Parameters of Patients with Sacroiliac Joint Pain.
|
PLoS One
|
2015
|
0.75
|
|
42
|
Positional Relations of the Cervical Vagus Nerve Revisited.
|
Neuromodulation
|
2017
|
0.75
|
|
43
|
A label-free LC/MS/MS-based enzymatic activity assay for the detection of genuine caspase inhibitors and SAR development.
|
J Biomol Screen
|
2013
|
0.75
|
|
44
|
NEUROGATE: a new MR-compatible device for realizing minimally invasive treatment of intracerebral tumors.
|
Comput Aided Surg
|
2004
|
0.75
|
|
45
|
NanoStore: a concept for logistical improvements of compound handling in high-throughput screening.
|
J Biomol Screen
|
2005
|
0.75
|